Home > Haematology > EHA 2021 > Thrombotic and Thrombocytopenic Disorders including COVID-19 related > COVID-19 vaccine-induced immune thrombotic thrombocytopenia: discovery and diagnosis

COVID-19 vaccine-induced immune thrombotic thrombocytopenia: discovery and diagnosis

Presented By
Prof. Sabine Eichinger, Medical University Hospital of Vienna, Austria
Conference
EHA 2021
The first diagnosis of vaccine-induced immune thrombotic thrombocytopenia (VITT) and updated patient characteristics from Europe and Canada were presented. An acronym that might aid in diagnosis is VITT: Vaccine, Interval, Thrombosis, Thrombocytopaenia. Prof. Sabine Eichinger (Medical University Hospital of Vienna, Austria) reviewed the discovery of VITT and discussed algorithms for VITT diagnosis and treatment [1]. The first diagnosed case of VITT was a 49-year-old woman. On 17 February 2021, she received the first COVID-19 vaccine (ChAdOx1 nCov-19, AstraZeneca) and experienced mild fever, headache, and myalgia, which resolved after 2–3 days. From day 5, she experienced increasing abdominal pain, chills, and vomiting. In the morning of day 10, the patient was admitted to a local hospital and tested negative for SARS-CoV-2. She had a low platelet count (18/mm³) and elevated D-dimer (35 µg/mL), gamma-GT (141 U/L), and CRP (8.8 mg/dL). Computer tomography (...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on